Critical Supply Strategies for Biologic/Biosimilar Studies

Format: PDF file

This content is provided by Catalent, and any views and opinions expressed do not necessarily reflect those of

Critical Supply Strategies for Biologic/Biosimilar Studies

As more approved biologics near patent expiration, the race to be first to market with a biosimilar alternative will intensify. Delays encountered during clinical studies can have a serious impact on competitive advantage, speed to market and the availability of lower-cost alternatives for patients.

Successfully maintaining product integrity and reliability of supply is a complex endeavor and one that is especially challenging for biologic and biosimilar studies.

Free on-demand webinar hosted by Catalent clinical logistics and supply chain experts Mark Woolf & John Samuels

Latest content from Catalent

Related resources from Catalent

Show more

Supplier info centre